NCT05297760View on ClinicalTrials.gov

Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Rhinitis, Allergic, SeasonalRhinitis; Allergic, With AsthmaAllergic RhinitisAllergic Rhinitis Due to Grass PollenAllergic Asthma
Interventions
BIOLOGICAL

Polvac Grass+Rye

Suspension of micro crystalline tyrosine with grass and rye pollen allergen

DRUG

Saline 0.9%

Physiological saline solution for use as vehicle for the biological drug (Polvac Grass+Rye) or as placebo.

Trial Locations (1)

8091

University Hospital Zurich, Zurich

All Listed Sponsors
collaborator

University of Aarhus

OTHER

lead

University of Zurich

OTHER